Genetics of Alzheimer’s disease

Overview of Alzheimer’s Disease Neuroimaging Initiative and future clinical trials

Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, Diaz A, Flenniken D, Green RC, Harvey DJ, Jack CR, Jagust W, Lee EB, Morris JC, Nho K, Nosheny R, Okonkwo OC, Perrin PJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Veitch DP, for the Alzheimer's Disease Neuroimaging Intitiative

Alzheimer's and Dementia December 2024

The Alzheimer’s Disease Neuroimaging Intitiative in the era of Alzheimer’s disease treatment: A review of ADNI studies from 2021 to 2022

Veitch DP, Weiner, MW, Miller M, Aisen PS, Ashford MA, Beckett LA, Green RC, Harvey D, Jack CR Jr., Jagust W, Landau SM, Morris JC, Nho KT, Nosheny R, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin A, Shaw LM, Toga AW, Tosun D for the Alzheimer's Disease Neuroimaging Initiative

The Journal of the Alzheimer's Association August 2023

Disclosing APOE genotype to individuals at risk for Alzheimer’s disease

Roberts JS, Green RC

Alzheimer's Disease International September 2021

Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease

Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia: The Journal of the Alzheimer's Association September 2021

How will Aducanumab approval impact Alzheimer’s disease research?

Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust William, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Mindt MR, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Journal of Prevention of Alzheimer's Disease July 2021

Genome-wide association study of rate of cognitive decline in Alzheimer’s patients identifies novel genes and pathways

Sherva R, Gross A, Mukherjee S, Koesterer R, Amouyel P, Bellenguez C, Bennett D, Chibnik L, Cruchaga C, Farrer L, Kraft P, Mayeux R, Munsie L, Newhouse S, Saykin A, Schellenberg G, the Alzheimer’s Disease Genetics Consortium, Crane PK, Green RC

Alzheimer's & Dementia June 2020

Disclosing genetic risk of Alzheimer’s dementia to individuals with mild cognitive impairment

Christensen KD, Karlawish J, Roberts JS, Uhlmann WR, Harkins K, Wood EM, Obisesan TO, Le LQ, Cupples LA, Zoltick ES, Johnson MS, Bradbury MK, Waterston LB, Chen CA, Feldman S, Perry DL, Green RC

Alzheimer's & Dementia: Translational Research & Clinical Interventions March 2020

Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families

Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, Cupples LA, Green RC, DeCarli C, Farrer LA

Neurobiology of Aging February 2011

Genetic architecture of subcortical brain structures in 38,854 individuals worldwide

Satizabal CL, Adams HHH, Hibar DP, White CC, Stein JL, Scholz M, Sargurupremraj M, Jahanshad N, Smith AV, Bis JC, Jian X, Luciano M, Hofer E, Teumer A, Lee SJ, Yang J, Yanek LR, Lee TV, Li S, et al.

Nature Genetics October 2019

Bioethicists worried patients couldn’t handle their own genetic testing results. They were (mostly) wrong

STAT |

July 2019

Press

The first major randomized clinical trial on the effect of disclosing genetic information found that people who decided to learn about their genetic risk of developing Alzheimer’s disease did not experience large, negative psychological impacts.

Diagnosis and Management of Alzheimer’s Disease and Other Dementias

Book

Robert C. Green

January 2005

Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates AB, tau, immunity and lipid processing

Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V… Green RC…Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert J-C, Pericak-Vance MA

Nature Genetics March 2019

Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairens NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Peterson RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ

Alzheimer's & Dementia February 2019

Communication predictors of patient and companion satisfaction with Alzheimer’s genetic risk disclosure

Guan Y, Roter DL, Erby LH, Wolff JL, Gitlin LN, Roberts JS, Green RC, Christensen KD

Journal of Health Communication October 2018

The impact of genetic counselors’ use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer’s disease

Guan Y, Roter DL, Wolff JL, Gitlin LN, Christensen KD, Roberts JS, Green RC, Erby LH.

Patient Education and Counseling May 2018

Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping: the Alzheimer’s Disease Neuroimaging Initiative

Ridge PG, Wadsworth ME, Miller JB, Saykin AJ, Green RC, for the Alzheimer’s Disease Neuroimaging Inititiave, Kauwe JSK

Alzheimer's & Dementia April 2018

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Weiner MW, Green RC, Toga AW, Saykin AJ for the Alzheimer’s Disease Neuroimaging Initiative

BMC Medical Genomics October 2017

A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone

Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Butson MB, Fasaye GA, Hiraki S, Chen CA, Siebert U, Cook-Deegan R, Green RC.

Genetics in Medicine July 2017

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease

Sims R, van der Lee SJ, Naj AC...(232 authors)...Green RC...(215 authors)...Seshadri S, Williams J, Schellenberg GD.

Nature Genetics July 2017

G2P Newsletter May 2017

Genomes2People |

May 2017

G2P News

In spring, The New York Times highlighted G2P’s work with REVEAL-SCAN, team members participated in a 10k marathon to raise money for genetic research, and G2P researchers published a new article on direct-to-consumer testing.

New gene tests pose a threat to insurers

New York Times |

May 2017

Press

Dr. Green has found that people who learn they have the ApoE4 gene fare just as well if they get the results without counseling.those who learned they had the gene variant — Ms. Reilly was one of them — were nearly six times more likely to buy long-term care insurance than those who did not.

Disclosing genetic risk of Alzheimer’s disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study

Guan Y, Roter DL, Erby LH, Wolff JL, Gitlin LN, Roberts JS, Green RC, Christensen KD

Patient Education and Counseling May 2017

Crowdsourced estimation of cognitive decline and resilience in Alzheimer’s disease

Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme K, Boutros PC, Caberlotto L, Caloian C, Campbell F, Neto EC, Chang Y-C, Chen B, Chen C-Y, Chien T-Y, Clark T, Das S, Davatzikos C, Deng J, Dillenberger D, Dobson RJB, Don Q, Doshi J, Duma D, Errico R, Erus G, Everett E, Fardo DW, Friend SH, Fröhlich H, Gan J, St. George-Hyslop P, Ghosh SS, Glaab E, Green RC, Guan Y, Hong M-Y, Huang C, Hwang J, Ibrahim J, Inglese P, Jiang Q, Katsumata Y, Kauwe JSK et al.

Alzheimer's & Dementia May 2016

Genomes2People: a roadmap for genomic medicine

Front Line Genomics |

May 2016

Press

An overview and summary of the main projects that are being conducted within the G2P program, both past and present. This article also includes the progract managers and research assistants on each major project.

Global and local ancestry in African Americans: Implications for Alzheimer’s disease risk

Hohman TJ, Cooke-Bailey JN, Reitz C, Jun G, Naj A, Beecham GW, Liu Z, Carney RM, Vance JM, Cuccaro ML, Rajbhandary R, Vardarajan BN, Wang L-S, Valladares O, Lin C-F, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue MW, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RCP, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hardy J, Hendrie HC, Hall KS, Goate AM, Lang R, Byrd GS, Kukull WA, Foroud TM, Farrer LA, Martin ER, Pericak-Vance MA, Schellenberg GD, Mayeux R, Haines JL, Thornton-Wells TA

Alzheimer's & Dementia March 2016

The executive prominent/memory prominent spectrum of Alzheimers disease is highly heritable

Mez J, Mukherjee S, Thornton T, Fardo DW, Trittschuh E, Sutti S, Sherva R, Kauwe JS, Jaz AC, Beecham GW, Gross A, Saykin AJ, Green RC, Crane PK.

Neurobiology of Aging February 2016

More information on genetic risks is actually reassuring, study finds

Boston Globe |

February 2016

Press

Within the REVEAL-SCAN study, one group of participants are given back the results on Alzheimer’s and additional heart disease information. Patients who are receiving the additional information are finding it reassuring that they can take measures to prevent at least one of their possible conditions if they have mutations for both.

No worries! CAD risk disclosure OK at Alzheimer’s genotyping

Medscape |

January 2016

Press

Through the REVEAL study, researchers were testing to see how participants anxiety, depression, and test-related distress would be affected by knowing their genetic results of Alzheimer’s Disease and Coronary artery disease.

Disclosure of incidental genetic findings can have positive impact for patients

Brigham Women's Hospital |

January 2016

Press Release

A new study has found that providing unanticipated information about risk of coronary artery disease during a genetic risk assessment for Alzheimer’s disease helped some participants cope with their results, and also motivated participants to make changes to their health behaviors. The results of the randomized controlled study are published online in the journal Annals of … Continued

With genetic testing results, more may be better

Reuters Health |

January 2016

Press

The research study conducted through REVEAL might help researchers and doctors decide how much information to give patients based on genetic testing results

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

Harkins K, Sankar P, Sperlin R, Grill JD, Green RC, Johnson KA, Healy M, Karlawish J

Alzheimer's Research & Therapy September 2015

GWAS of longitudinal amyloid accumulation on [18F]-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP

Ramanan VK, Risacher SL, Nho K, Kim A, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, DeJager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR, Toga AW, Green RC, Jagust JW, Weiner MW, Saykin AJ

Brain August 2015

Protective variant for hippocampal atrophy identified by whole exome sequencing

Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR, Jr., Weiner MW, Baldwin CT, Lunetta KL, Farrer LA, Study M, Furney SJ, Lovestone S, Simmons A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, AddNeuroMed C, McDonald BC, Farlow MR, Ghetti B, Indiana M, Aging S, Huentelman MJ, Saykin AJ, Alzheimer's Disease Neuroimaging Initiative

Annals of Neurology March 2015